Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.

NCT Number	NCT06160128
Lead Sponsor	VA Office of Research and Development Collaborators: Biomedical Advanced Research and Development Authority, Food and Drug Administration (FDA)
Conditions	COVID-19, SARS-CoV-2 Infection, RSV, Influenza
Enrollment	400,000 participants
Start Date	2022-09-26
Primary Completion	2026-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-10